

Jonas Lategahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/475525/publications.pdf>

Version: 2024-02-01

24
papers

781
citations

623188

14
h-index

610482

24
g-index

24
all docs

24
docs citations

24
times ranked

1090
citing authors

#	ARTICLE	IF	CITATIONS
1	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6643-6655.	2.9	12
2	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. <i>Cancer Discovery</i> , 2021, 11, 108-125.	7.7	47
3	Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 40-51.	2.9	9
4	Targeting Her2-insYVMA with Covalent Inhibitorsâ€”A Focused Compound Screening and Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11725-11755.	2.9	7
5	Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2484-2490.	1.3	26
6	Characterization of Covalent Pyrazolopyrimidineâ€”MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5541-5546.	2.9	12
7	Targeting the MKK7â€”JNK (Mitogen-Activated Protein Kinase Kinase 7â€”c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2843-2848.	2.9	18
8	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. <i>Chemical Science</i> , 2019, 10, 10789-10801.	3.7	25
9	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. <i>Scientific Reports</i> , 2019, 9, 14.	1.6	28
10	Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14718-e14718.	0.8	1
11	Lessons To Be Learned: The Molecular Basis of Kinaseâ€”Targeted Therapies and Drug Resistance in Nonâ€”Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 2307-2313.	7.2	36
12	Lektion gelernt? Die molekularen Grundlagen von Kinaseâ€”gerichteten Therapien und Wirkstoffresistenz im nichtâ€”kleinzelligen Lungenkrebs. <i>Angewandte Chemie</i> , 2018, 130, 2329-2335.	1.6	1
13	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	5.8	107
14	Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates. <i>Bioconjugate Chemistry</i> , 2018, 29, 2671-2678.	1.8	10
15	RASPELD to Perform Highâ€”End Screening in an Academic Environment toward the Development of Cancer Therapeutics. <i>ChemMedChem</i> , 2018, 13, 2065-2072.	1.6	5
16	C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 779-782.	1.3	56
17	An Unusual Intramolecular Halogen Bond Guides Conformational Selection. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 9970-9975.	7.2	12
18	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2361-2372.	2.9	43

#	ARTICLE	IF	CITATIONS
19	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5613-5637.	2.9	77
20	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7725-7744.	2.9	24
21	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. <i>Angewandte Chemie</i> , 2016, 128, 11069-11073.	1.6	4
22	Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 10909-10912.	7.2	54
23	Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 2-5.	1.3	75
24	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6844-6863.	2.9	92